{
    "clinical_study": {
        "@rank": "125909", 
        "acronym": "KWG", 
        "arm_group": [
            {
                "arm_group_label": "1 gram of White Korean Ginseng", 
                "arm_group_type": "Experimental", 
                "description": "1 gram of White Korean Ginseng"
            }, 
            {
                "arm_group_label": "3 grams of White Korean Ginseng", 
                "arm_group_type": "Experimental", 
                "description": "3 grams of White Korean Ginseng"
            }, 
            {
                "arm_group_label": "6 grams of White Korean Ginseng", 
                "arm_group_type": "Experimental", 
                "description": "6 grams of White Korean Ginseng"
            }, 
            {
                "arm_group_label": "3 grams of Wheat Bran Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3 grams of Wheat Bran Control"
            }, 
            {
                "arm_group_label": "500mg of Korean Red Ginseng", 
                "arm_group_type": "Active Comparator", 
                "description": "500mg of Korean Red Ginseng"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is a Phase-I like double blind randomized placebo controlled crossover design\n      trial. The objective is to assess the dose response relationship on glycemic and vascular\n      effects of an acutely administered Korean White Ginseng (KWG)(Panax C.A. Meyer) in\n      individuals with metabolic syndrome or type 2 diabetes . Twenty seven subjects with Type 2\n      Diabetes (Key inclusion criteria: HbA1c \u22648.5%)or metabolic syndrome (Key inclusion criteria:\n      as defined by The US National Cholesterol Education Program Adult Treatment Panel III)will\n      be recruited for the study."
        }, 
        "brief_title": "Acute Dose Response of Korean White Ginseng in Metabolic Syndrome or Type 2 Diabetes", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Metabolic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Metabolic Syndrome X"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study hypothesizes that KWG will dose dependently lower postprandial area under the\n      curve compared to negative control, as well as will dose dependently decrease postprandial\n      glycemia. It also assumes that use of KWG will dose dependently decrease aortic and brachial\n      blood pressure, aortic augmentation index, and mean arterial pressure, and improve left\n      ventricular ejection duration(ED) and subendocardial viability ratio (SEVR) compared to\n      control. Finally, it expects to notice an effect on subjective satiety levels and have no\n      significant adverse effects compared to control."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women\n\n          -  18-75 years old\n\n          -  BMI 25-35 kg/m2\n\n          -  Presence of type 2 diabetes (as defined by HbA1c \u22648.5%),treatment with diet or oral\n             hypoglycemic medication) OR\n\n          -  Presence of Metabolic Syndrome as defined by The US National Cholesterol -Education\n             Program Adult Treatment Panel III (NCEP III). As per NCEP III criteria, at  least\n             three of the following must be present:\n\n          -  central obesity: waist circumference \u2265 102 cm or 40 inches (male), \u2265 88 cm or 36\n             inches(female)\n\n          -  dyslipidemia: TG \u2265 1.7 mmol/L (150 mg/dl);\n\n          -  dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female) blood pressure \u2265 130/85\n             mmHg; fasting plasma glucose \u2265 6.1 mmol/L (110 mg/dl)\n\n        Exclusion Criteria:\n\n          -  BMI >35 kg/m2\n\n          -  Hypertensive (brachial systolic BP \u2265140mmHg and/or diastolic BP \u226590mmHg)\n\n          -  Pregnant women, or those at risk of pregnancy, or breastfeeding at the time of the\n             study.\n\n          -  Women of childbearing age that do not use acceptable method of birth control (ie.\n             abstinence, implants, injectables, oral contraceptives, IUDs etc).\n\n          -  Chronic conditions including: liver disease, cancer, heavy alcohol use, bleeding\n             disorders, history of angina, congestive heart failure, coronary revascularization,\n             peripheral vascular disease, retinopathy, kidney disease or coronary/cerebrovascular\n             event; chronic use of medications including blood-thinners, SSRIs, MAO inhibitors,\n             medications affecting NO synthesis (eg. Viagra)\n\n          -  Allergy or sensitivity to the placebo (wheat bran), ginseng or gelatin used in the\n             capsules.\n\n          -  Use of any ginseng products within three days preceding the study and during the\n             study.\n\n          -  Allergies to Panax species, their constituents or to other members of the Araliaceae\n             family.\n\n        The use of additional NHPs that may affect blood pressure or blood glucose Individuals\n        suffering from glucose-galactose malabsorption syndrome."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01699074", 
            "org_study_id": "182629"
        }, 
        "intervention": [
            {
                "arm_group_label": "1 gram of White Korean Ginseng", 
                "description": "1 gram of White Korean Ginseng", 
                "intervention_name": "1 gram of White Korean Ginseng", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "3 grams of White Korean Ginseng", 
                "description": "3 grams of White Korean Ginseng", 
                "intervention_name": "3 grams of White Korean Ginseng", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "6 grams of White Korean Ginseng", 
                "description": "6 grams of White Korean Ginseng", 
                "intervention_name": "6 grams of White Korean Ginseng", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "3 grams of Wheat Bran Control", 
                "description": "3 grams of Wheat Bran Control", 
                "intervention_name": "3 grams of Wheat Bran Control", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "500mg of Korean Red Ginseng", 
                "description": "500mg of Korean Red Ginseng", 
                "intervention_name": "500mg of Korean Red Ginseng", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Korean White Ginseng", 
            "Type 2 diabetes", 
            "Metabolic syndrome"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5B 1W8"
                }, 
                "name": ": Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "5", 
        "official_title": "Acute Dose Response Effects of Korean White Ginseng (Panax Ginseng C.A. Meyer) on Cardiovascular Disease Risk Factors in Individuals With Metabolic Syndrome or Type 2 Diabetes", 
        "other_outcome": {
            "description": "To evaluate the acute effect of KWG treatments on subjective satiety scores to determine any potential effects on appetite control mechanisms compared to controls. Symptoms questionnaire will assess potential adverse effects of treatments (safety)", 
            "measure": "KWG and satiety", 
            "safety_issue": "No", 
            "time_frame": "4 hours"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the acute dose response effect of KWG on blood glucose Area under the Curve (AUC) compared to controls in individuals with Metabolic syndrome or Type 2 Diabetes To evaluate the acute effect of KWG treatments on arterial stiffness as measured by aortic augmentation index (AIx)", 
            "measure": "Effect of KWG on vascular and glycemic measures", 
            "safety_issue": "No", 
            "time_frame": "3 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01699074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the acute effect of Korean White ginseng  treatments on peak and postprandial glycemia measures.To evaluate the acute effect of KWG treatments on aortic and brachial blood pressure To evaluate the acute effect of KWG treatments on heart rate, mean arterial pressure, left ventricular ejection duration (ED) and subendocardial viability ratio (SEVR) - a surrogate marker of myocardial perfusion", 
            "measure": "Effect of KWG on vascular and glycemic measures", 
            "safety_issue": "No", 
            "time_frame": "4 hours"
        }, 
        "source": "St. Michael's Hospital, Toronto", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Michael's Hospital, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}